Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while YieldMax TSLA Option Income Strategy ETF trades at $21.17 (market cap $675.95M). The key difference: Maravai LifeSciences Holdings Inc. Class A Common Stock is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and YieldMax TSLA Option Income Strategy ETF for 45 Days on average.
| MRVI | TSLY | |
|---|---|---|
Market Cap | $972.90M | $675.95M |
Volume | 4,325,710 | 216,837 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $43.35 |
52-Week Low | $2.83 | $20.49 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
TSLY trades at $22.11, down 0.58% with a bearish technical signal from moving averages. The ETF maintains consistent weekly dividend distributions averaging $0.21-0.26, though recent news highlights concerns about underperformance relative to Tesla's stock gains. Technical indicators show neutral oscillators with key support at $22 and resistance at $23.
The outlook remains cautious as TSLY faces structural challenges capturing Tesla's upside while providing income. Investors should weigh the high dividend yield against potential capital erosion during Tesla rallies. Key risks include volatility regime changes and the ETF's option strategy limitations in strong bull markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
